Toxicity evaluation of difluoromethylornithine: Doses for chemoprevention trials

Charles Lawrence Loprinzi, Edward M. Messing, Judith R. O'Fallon, Michael A. Poon, Richard R. Love, Susan K. Quella, Donald L. Trump, Roscoe F. Morton, Paul Novotny

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

This intergroup trial was developed to determine the toxicity of relatively low doses of difluoromethylornithine (DFMO) administered to humans for 1 year. The goal was to find an appropriate DFMO dose for use in human chemoprevention trials. Patients with resected superficial bladder cancers were studied. Following stratification, they were randomized to daily DFMO doses of 0.125, 0.25,0.5, or 1.0 g/day for a planned period of 1 year. Patients were followed closely for evidence of drug toxicity. Seventy-six patients were evenly randomized (19 per group) to receive each dose of DFMO. Forty-nine patients received DFMO for more than 200 days while 35 received the drug for ≥350 days. No substantial drug-related toxicity was observed at any dose. DFMO doses of ≤1 g/day for periods up to 1 year appear to be without significant toxicity in most patients. This dose range may be appropriate for use in future human cancer chemoprevention trials.

Original languageEnglish (US)
Pages (from-to)371-374
Number of pages4
JournalCancer Epidemiology Biomarkers and Prevention
Volume5
Issue number5
StatePublished - 1996

Fingerprint

Eflornithine
Chemoprevention
Drug-Related Side Effects and Adverse Reactions
Urinary Bladder Neoplasms
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Loprinzi, C. L., Messing, E. M., O'Fallon, J. R., Poon, M. A., Love, R. R., Quella, S. K., ... Novotny, P. (1996). Toxicity evaluation of difluoromethylornithine: Doses for chemoprevention trials. Cancer Epidemiology Biomarkers and Prevention, 5(5), 371-374.

Toxicity evaluation of difluoromethylornithine : Doses for chemoprevention trials. / Loprinzi, Charles Lawrence; Messing, Edward M.; O'Fallon, Judith R.; Poon, Michael A.; Love, Richard R.; Quella, Susan K.; Trump, Donald L.; Morton, Roscoe F.; Novotny, Paul.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 5, No. 5, 1996, p. 371-374.

Research output: Contribution to journalArticle

Loprinzi, CL, Messing, EM, O'Fallon, JR, Poon, MA, Love, RR, Quella, SK, Trump, DL, Morton, RF & Novotny, P 1996, 'Toxicity evaluation of difluoromethylornithine: Doses for chemoprevention trials', Cancer Epidemiology Biomarkers and Prevention, vol. 5, no. 5, pp. 371-374.
Loprinzi, Charles Lawrence ; Messing, Edward M. ; O'Fallon, Judith R. ; Poon, Michael A. ; Love, Richard R. ; Quella, Susan K. ; Trump, Donald L. ; Morton, Roscoe F. ; Novotny, Paul. / Toxicity evaluation of difluoromethylornithine : Doses for chemoprevention trials. In: Cancer Epidemiology Biomarkers and Prevention. 1996 ; Vol. 5, No. 5. pp. 371-374.
@article{62891094b2f2439bbf44d6a30edea9da,
title = "Toxicity evaluation of difluoromethylornithine: Doses for chemoprevention trials",
abstract = "This intergroup trial was developed to determine the toxicity of relatively low doses of difluoromethylornithine (DFMO) administered to humans for 1 year. The goal was to find an appropriate DFMO dose for use in human chemoprevention trials. Patients with resected superficial bladder cancers were studied. Following stratification, they were randomized to daily DFMO doses of 0.125, 0.25,0.5, or 1.0 g/day for a planned period of 1 year. Patients were followed closely for evidence of drug toxicity. Seventy-six patients were evenly randomized (19 per group) to receive each dose of DFMO. Forty-nine patients received DFMO for more than 200 days while 35 received the drug for ≥350 days. No substantial drug-related toxicity was observed at any dose. DFMO doses of ≤1 g/day for periods up to 1 year appear to be without significant toxicity in most patients. This dose range may be appropriate for use in future human cancer chemoprevention trials.",
author = "Loprinzi, {Charles Lawrence} and Messing, {Edward M.} and O'Fallon, {Judith R.} and Poon, {Michael A.} and Love, {Richard R.} and Quella, {Susan K.} and Trump, {Donald L.} and Morton, {Roscoe F.} and Paul Novotny",
year = "1996",
language = "English (US)",
volume = "5",
pages = "371--374",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Toxicity evaluation of difluoromethylornithine

T2 - Doses for chemoprevention trials

AU - Loprinzi, Charles Lawrence

AU - Messing, Edward M.

AU - O'Fallon, Judith R.

AU - Poon, Michael A.

AU - Love, Richard R.

AU - Quella, Susan K.

AU - Trump, Donald L.

AU - Morton, Roscoe F.

AU - Novotny, Paul

PY - 1996

Y1 - 1996

N2 - This intergroup trial was developed to determine the toxicity of relatively low doses of difluoromethylornithine (DFMO) administered to humans for 1 year. The goal was to find an appropriate DFMO dose for use in human chemoprevention trials. Patients with resected superficial bladder cancers were studied. Following stratification, they were randomized to daily DFMO doses of 0.125, 0.25,0.5, or 1.0 g/day for a planned period of 1 year. Patients were followed closely for evidence of drug toxicity. Seventy-six patients were evenly randomized (19 per group) to receive each dose of DFMO. Forty-nine patients received DFMO for more than 200 days while 35 received the drug for ≥350 days. No substantial drug-related toxicity was observed at any dose. DFMO doses of ≤1 g/day for periods up to 1 year appear to be without significant toxicity in most patients. This dose range may be appropriate for use in future human cancer chemoprevention trials.

AB - This intergroup trial was developed to determine the toxicity of relatively low doses of difluoromethylornithine (DFMO) administered to humans for 1 year. The goal was to find an appropriate DFMO dose for use in human chemoprevention trials. Patients with resected superficial bladder cancers were studied. Following stratification, they were randomized to daily DFMO doses of 0.125, 0.25,0.5, or 1.0 g/day for a planned period of 1 year. Patients were followed closely for evidence of drug toxicity. Seventy-six patients were evenly randomized (19 per group) to receive each dose of DFMO. Forty-nine patients received DFMO for more than 200 days while 35 received the drug for ≥350 days. No substantial drug-related toxicity was observed at any dose. DFMO doses of ≤1 g/day for periods up to 1 year appear to be without significant toxicity in most patients. This dose range may be appropriate for use in future human cancer chemoprevention trials.

UR - http://www.scopus.com/inward/record.url?scp=0029920326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029920326&partnerID=8YFLogxK

M3 - Article

C2 - 9162303

AN - SCOPUS:0029920326

VL - 5

SP - 371

EP - 374

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 5

ER -